| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.11.1.183 |
| P953 | full work available at URL | https://www.ahajournals.org/doi/pdf/10.1161/01.ATV.11.1.183 |
| P698 | PubMed publication ID | 1670989 |
| P50 | author | Anders Hamsten | Q30421754 |
| Sally J. Dawson | Q39184132 | ||
| P2093 | author name string | B. Wiman | |
| S. Humphries | |||
| A. Henney | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cardiology and cardiovascular medicine | Q96320350 |
| plasminogen | Q107129060 | ||
| P304 | page(s) | 183-190 | |
| P577 | publication date | 1991-01-01 | |
| P1433 | published in | Arteriosclerosis and thrombosis : a journal of vascular biology | Q27709770 |
| P1476 | title | Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity | |
| P478 | volume | 11 |
| Q95437116 | Q95437116 |
| Q42460350 | 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study |
| Q33919345 | 4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study |
| Q44576903 | 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke |
| Q41821585 | A Case of Unexplained Cerebral Sinus Thrombosis in a 22-Year-Old Obese Caucasian Woman |
| Q50981804 | A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. |
| Q63439568 | ACE, PAI-1, decorin and Werner helicase genes are not associated with the development of renal disease in European patients with Type 1 diabetes |
| Q46707808 | An Insertion/Deletion polymorphism in the promoter region of the plasminogen activator inhibitor-1 gene is associated with plasma levels but not with stroke risk in the elderly |
| Q24804221 | An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation |
| Q51019729 | Analysis of plasma fibrinolysis in the patients with acute cerebral infarction. |
| Q64321707 | Association Between - 675 ID, 4G/5G PAI-1 Gene Polymorphism and Pregnancy Loss: A Systematic Review |
| Q48632959 | Association between 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene with stroke or encephalopathy after cardiac surgery |
| Q36870194 | Association of G894T eNOS, 4G/5G PAI and T1131C APOA5 polymorphisms with susceptibility to myocardial infarction in Morocco |
| Q37634825 | Association of plasminogen activator inhibitor-1 gene polymorphism with inflammatory bowel disease in Iranian Azeri Turkish patients |
| Q47922833 | Association of the plasminogen activator inhibitor-1 gene 4G/5G polymorphism with ST elevation acute myocardial infarction in young patients. |
| Q36249248 | Atherosclerotic and thrombotic genetic and environmental determinants in Egyptian coronary artery disease patients: a pilot study. |
| Q41996464 | Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia. |
| Q81556139 | Blood coagulation and fibrinolysis in male patients with hypogonadotropic hypogonadism: plasma factor V and factor X activities increase in hypogonadotropic hypogonadism |
| Q34180954 | Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment |
| Q27011330 | Cardiac allograft vasculopathy: diagnosis, therapy, and prognosis |
| Q33697706 | Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems |
| Q24796861 | Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas |
| Q53849561 | Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes-thirty-three-year follow-up. |
| Q73422349 | Effects of dietary fat modification on fibrinogen, factor VII, and plasminogen activator inhibitor-1 activity in subjects with impaired glucose tolerance |
| Q51379514 | Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy. |
| Q35945275 | Factors associated with excessive bleeding in cardiopulmonary bypass patients: a nested case-control study |
| Q40406437 | Fibrinolysis and atherosclerosis |
| Q40582633 | Fibrinolysis and thrombosis |
| Q34027250 | Fibrinolytic function and coronary risk |
| Q59101064 | Functional stability of plasminogen activator inhibitor-1 |
| Q73681245 | Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease |
| Q36727806 | Genes and the development of vascular disease |
| Q40582647 | Genetic determinants of arterial thrombosis |
| Q35081846 | Hereditary and acquired defects in the fibrinolytic system associated with thrombosis |
| Q51573704 | Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients. |
| Q37786770 | Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease |
| Q73681235 | Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease |
| Q83363878 | Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI-1 gene |
| Q77227029 | Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-beta levels |
| Q35542242 | Inherited Thrombophilia: Impact on Human Reproduction |
| Q73218081 | Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction |
| Q73794532 | Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci |
| Q35489121 | Meta-analysis of the association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss |
| Q28365290 | Moderate alcohol consumption and coronary heart disease: a review |
| Q55260837 | Molecular assessment of some cardiovascular genetic risk factors among Iraqi patients with ischemic heart diseases. |
| Q35479955 | PAI-1 4G/5G polymorphism and coronary artery disease risk: a meta-analysis |
| Q34599478 | PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis |
| Q34461462 | PAI-1 and t-PA/PAI-1 complex potential markers of fibrinolytic bleeding after cardiac surgery employing cardiopulmonary bypass |
| Q71718204 | Pathophysiology of fibrinolysis |
| Q33832519 | Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity |
| Q34384926 | Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease |
| Q34229863 | Plasminogen activator inhibitor-1 4G/5G gene polymorphism and coronary artery disease in the Chinese Han population: a meta-analysis |
| Q34547819 | Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis |
| Q80848557 | Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease |
| Q51802957 | Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis. |
| Q34439639 | Plasminogen activator inhibitor-1 gene polymorphism in Iranian Azeri Turkish patients with FMF disease and its association with amyloidosis. |
| Q58052078 | Plasminogen activator inhibitor-1 polymorphisms (−844 G>A and HindIII C>G) in systemic lupus erythematosus: association with clinical variables |
| Q74519744 | Plasminogen-activator-inhibitor-1 promoter polymorphism as a risk factor for adult periodontitis in non-smokers |
| Q83785787 | Platelet glycoprotein IIIA PIA2 polymorphism is associated with ST elevation acute myocardial infarction in young Mexican population |
| Q41682753 | Polymorphisms of coagulation/fibrinolysis genes: gene environment interactions and vascular risk |
| Q73695262 | Prospective study of fibrinolytic markers and venous thromboembolism |
| Q35113270 | Prothrombotic determinants of coronary atherothrombosis |
| Q34376910 | Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis |
| Q36371240 | Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women |
| Q51579395 | Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians. |
| Q34212957 | Relationship of metabolic syndrome and its components with -844 G/A and HindIII C/G PAI-1 gene polymorphisms in Mexican children. |
| Q34981278 | Role of genetic polymorphisms in tumour angiogenesis |
| Q33613823 | Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease |
| Q33959926 | Significant associations of PAI-1 genetic polymorphisms with osteonecrosis of the femoral head |
| Q83200066 | The Renin-Angiotensin and fibrinolytic systems co-conspirators in the pathogenesis of ischemic cardiovascular disease |
| Q42465243 | The effect of number of days in culture and plasminogen activator inhibitor-1 (PAI-1) 4G/5G genotype on PAI-1 antigen release by cultured human umbilical vein endothelial cells |
| Q34421664 | The mechanisms of thrombotic risk induced by hormone replacement therapy |
| Q31899830 | The plasminogen activator inhibitor (PAI)-1 promoter 4G/4G genotype is not associated with ischemic stroke in a population of German children. Childhood Stroke Study Group |
| Q37423754 | The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. |
| Q34107537 | The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies |
| Q43064983 | Thrombosis and inflammatory bowel disease-the role of genetic risk factors |
| Q33564092 | Venous thrombosis and prothrombotic factors in inflammatory bowel disease |
| Q33735850 | t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension |
Search more.